Dendreon Corporation Announces Initial Public Offering.Business Editors SEATTLE--(BUSINESS WIRE)--June 16, 2000 Dendreon Corporation (Nasdaq:DNDN) today announced the initial public offering of 4,500,000 shares of common stock at $10.00 per share. Prudential Vector Healthcare Group, a unit of Prudential Securities, acted as lead manager and SG Cowen Securities Corporation and Pacific Growth Equities, Inc. acted as co-managers. The Company has granted the underwriters an option to purchase up to 675,000 shares of common stock to cover over-allotments, if any. Dendreon Corporation, based in Seattle, Washington, discovers and develops novel products for the treatment of cancer through its innovative manipulation of the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Dendreon is focused on the development of novel therapeutic vaccines and antibodies for the treatment of cancer using proprietary antigen discovery, antigen engineering and dendritic cell dendritic cell n. 1. A cell that has branching processes. 2. Any of the cells in the neural crest of the embryonic ectoderm having extensive processes and developing early as producers of melanin. technologies. The Company is conducting a Phase III trial for Provenge(TM), its prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. vaccine, and Phase II trials for Mylovenge(TM), its therapeutic vaccine for B-cell malignancies, including multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility . A copy of the prospectus may be obtained from Prudential Securities, 111 8th Avenue, 5th Floor, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , New York 10011, FAX: 212/776-8144. This press release is not an offer to sell or a solicitation of an offer to buy these securities in any state or jurisdiction in which such an offer, solicitation, or sale is not permitted. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion